We are a clinical-stage biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of muscular wasting and diabetes, obesity, and other metabolic diseases and associated comorbidities, which impact millions globally.

By harnessing our groundbreaking technology, we aim to transform therapeutic options across a spectrum of metabolic disorders, through the development of small molecules with distinct and novel signaling profiles.

Our dedication to innovation, coupled with a highly skilled team, has resulted in a strong IP-portfolio and pipline. Our lead asset has advanced through Phase I clinical trials and is ready for next step. Additionally, we are advancing other promising compounds, currently in preclinical stages, and as well showing remarkable potential in repartitioning and altering muscle metabolism.

Since our inception, we have successfully raised over EUR 20 million in funding from prominent investors, including Flerie Invest, Korea Investment Partners (KIP), and a network of private investors. Our work has also been recognized by international organizations, securing over EUR 1.5 million in non-dilutive grants from Eurostars and SweLife, affirming the groundbreaking nature of our receptor signaling discoveries.